Lead Compound Identification and Optimization
Start with the big picture
A lead compound is a starting point for optimization, not a finished medicine. Leads may come from natural products, synthetic libraries, repurposed drugs, endogenous ligands, or fragments; screening and other approaches help identify promising hits. Hit-to-lead work uses structure–activity relationship mapping and strategies such as bioisosteric replacement to improve activity and selectivity. Optimization also balances binding with solubility, permeability, metabolic stability, and toxicity. Drug-likeness guidance, early liability assessment, and structure-based design help prioritize changes. Because one improvement can affect other properties, analogs are generated and evaluated through iterative feedback, progressively refining the candidate.
What you'll learn
- Describe common sources of lead compounds and methods for identifying hits.
- Explain how structure–activity relationships guide lead optimization.
- Identify strategies for improving binding affinity and selectivity.
- Summarize how drug-likeness, ADME, toxicity, and pharmacokinetics shape optimization.
- Describe how structural design and iterative testing help prioritize analogs.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
